Afina for CAA/ARIA Prediction

About NeuroVision Imaging

NeuroVision Imaging is a private, venture-backed company addressing critical gaps in the neurology care pathway through a dual-platform strategy. Its core technology, the Afina Retinal Imaging platform, uses AI to detect amyloid signatures in the retina as a non-invasive biomarker for Alzheimer's and Cerebral Amyloid Angiopathy (CAA). Concurrently, the company's BrainHealth.net telehealth platform offers scalable diagnostic and managed services, including patient triage, preventative neurology coaching, genetic testing, and clinical trial matching, aiming to improve access and outcomes in cognitive healthcare.

Therapeutic Areas